BAX Stock Overview
Through its subsidiaries, provides a portfolio of healthcare products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Baxter International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.43 |
| 52 Week High | US$40.49 |
| 52 Week Low | US$26.25 |
| Beta | 0.63 |
| 1 Month Change | 6.62% |
| 3 Month Change | -9.00% |
| 1 Year Change | -11.41% |
| 3 Year Change | -59.53% |
| 5 Year Change | -64.80% |
| Change since IPO | 2,225.40% |
Recent News & Updates
Recent updates
The 'Goldilocks' Case For Baxter International
May 08Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden
May 02
Baxter: Messy, Yet Appealing, If New Management Can Deliver
Apr 21Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.17
Feb 21Baxter International: An Uncompelling Investment With High Debt
Jan 31Does Baxter International (NYSE:BAX) Have A Healthy Balance Sheet?
Jan 27Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?
Sep 05Baxter- Reiterating Our Buy Rating After A Promising Q2
Aug 07Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29
Aug 07Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
Jul 23Baxter: Why Investors Should Take Advantage Of The Low Valuation
Jul 16Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues
Jul 12Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29
May 30Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff
May 08Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts
Feb 23Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
Dec 12Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?
Oct 12Dividend Challengers Review: Baxter International
Aug 14Shareholder Returns
| BAX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.4% | -0.3% | -1.1% |
| 1Y | -11.4% | 6.7% | 9.1% |
Return vs Industry: BAX underperformed the US Medical Equipment industry which returned 9.7% over the past year.
Return vs Market: BAX underperformed the US Market which returned 11.1% over the past year.
Price Volatility
| BAX volatility | |
|---|---|
| BAX Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: BAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BAX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1931 | 38,000 | David Shafer | www.baxter.com |
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories.
Baxter International Inc. Fundamentals Summary
| BAX fundamental statistics | |
|---|---|
| Market cap | US$16.14b |
| Earnings (TTM) | -US$277.00m |
| Revenue (TTM) | US$10.77b |
Is BAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAX income statement (TTM) | |
|---|---|
| Revenue | US$10.77b |
| Cost of Revenue | US$6.55b |
| Gross Profit | US$4.22b |
| Other Expenses | US$4.50b |
| Earnings | -US$277.00m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | 39.22% |
| Net Profit Margin | -2.57% |
| Debt/Equity Ratio | 142.8% |
How did BAX perform over the long term?
See historical performance and comparisonDividends
Does BAX pay a reliable dividends?
See BAX dividend history and benchmarks| Baxter International dividend dates | |
|---|---|
| Ex Dividend Date | May 30 2025 |
| Dividend Pay Date | Jul 01 2025 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 39 days |
Does BAX pay a reliable dividends?
See BAX dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 10:01 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Baxter International Inc. is covered by 47 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Benjamin Yeoh | Atlantic Equities LLP |
| Daniel Owczarski | Avondale Partners |